JP2020537543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537543A5 JP2020537543A5 JP2020540682A JP2020540682A JP2020537543A5 JP 2020537543 A5 JP2020537543 A5 JP 2020537543A5 JP 2020540682 A JP2020540682 A JP 2020540682A JP 2020540682 A JP2020540682 A JP 2020540682A JP 2020537543 A5 JP2020537543 A5 JP 2020537543A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sequence
- seq
- itr
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 30
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 26
- 108020004707 nucleic acids Proteins 0.000 claims 26
- 102000039446 nucleic acids Human genes 0.000 claims 26
- 239000013608 rAAV vector Substances 0.000 claims 16
- 241000702421 Dependoparvovirus Species 0.000 claims 14
- 230000002401 inhibitory effect Effects 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108091026890 Coding region Proteins 0.000 claims 7
- 108090000565 Capsid Proteins Proteins 0.000 claims 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims 6
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- 102000004547 Glucosylceramidase Human genes 0.000 claims 4
- 108010017544 Glucosylceramidase Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 108700019146 Transgenes Proteins 0.000 claims 4
- 102000003802 alpha-Synuclein Human genes 0.000 claims 4
- 108090000185 alpha-Synuclein Proteins 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims 3
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims 3
- 108010006025 bovine growth hormone Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 230000001124 posttranscriptional effect Effects 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 102000019355 Synuclein Human genes 0.000 claims 2
- 108050006783 Synuclein Proteins 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 241000701447 unidentified baculovirus Species 0.000 claims 2
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023052515A JP2023086740A (ja) | 2017-10-03 | 2023-03-29 | ライソゾーム病の遺伝子治療 |
| JP2024218686A JP2025063034A (ja) | 2017-10-03 | 2024-12-13 | ライソゾーム病の遺伝子治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567296P | 2017-10-03 | 2017-10-03 | |
| US62/567,296 | 2017-10-03 | ||
| PCT/US2018/054225 WO2019070893A1 (en) | 2017-10-03 | 2018-10-03 | GENE THERAPIES FOR LYSOSOMAL DISORDERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052515A Division JP2023086740A (ja) | 2017-10-03 | 2023-03-29 | ライソゾーム病の遺伝子治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537543A JP2020537543A (ja) | 2020-12-24 |
| JP2020537543A5 true JP2020537543A5 (OSRAM) | 2021-11-11 |
| JP7254815B2 JP7254815B2 (ja) | 2023-04-10 |
Family
ID=65994357
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540682A Active JP7254815B2 (ja) | 2017-10-03 | 2018-10-03 | ライソゾーム病の遺伝子治療 |
| JP2023052515A Pending JP2023086740A (ja) | 2017-10-03 | 2023-03-29 | ライソゾーム病の遺伝子治療 |
| JP2024218686A Withdrawn JP2025063034A (ja) | 2017-10-03 | 2024-12-13 | ライソゾーム病の遺伝子治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052515A Pending JP2023086740A (ja) | 2017-10-03 | 2023-03-29 | ライソゾーム病の遺伝子治療 |
| JP2024218686A Withdrawn JP2025063034A (ja) | 2017-10-03 | 2024-12-13 | ライソゾーム病の遺伝子治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11802294B2 (OSRAM) |
| EP (1) | EP3692075A4 (OSRAM) |
| JP (3) | JP7254815B2 (OSRAM) |
| KR (1) | KR102693318B1 (OSRAM) |
| CN (1) | CN111542549A (OSRAM) |
| AU (2) | AU2018346104B2 (OSRAM) |
| BR (1) | BR112020006633A2 (OSRAM) |
| CA (1) | CA3078371A1 (OSRAM) |
| IL (2) | IL273776B2 (OSRAM) |
| MX (2) | MX2020003557A (OSRAM) |
| WO (1) | WO2019070893A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL273776B2 (en) | 2017-10-03 | 2025-06-01 | Prevail Therapeutics Inc | Gene therapies for lysosomal disorders |
| AU2018346102B2 (en) | 2017-10-03 | 2023-05-11 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| KR102709597B1 (ko) | 2017-10-03 | 2024-09-26 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
| MX2021009305A (es) | 2019-02-04 | 2021-11-04 | Freeline Therapeutics Ltd | Polinucleotidos. |
| AU2020270984B2 (en) | 2019-04-10 | 2025-11-20 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| CA3136004A1 (en) | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| KR20220099944A (ko) * | 2019-08-12 | 2022-07-14 | 푼다시온 파라 라 인베스티가시온 메디카 아플리카다 | 유전자 요법으로 파킨슨병과 같은 시누클레인병증을 치료하는 데 사용하기 위한 바이러스 입자 |
| CA3158516A1 (en) * | 2019-10-22 | 2021-04-29 | Applied Genetic Technologies Corporation | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegeneative diseases or disorders |
| JP2021083987A (ja) * | 2019-11-29 | 2021-06-03 | 株式会社三洋物産 | 遊技機 |
| AU2021292757A1 (en) * | 2020-06-18 | 2023-02-02 | Henrik BIVERSTAL | Cell lines secreting alpha-synuclein targeting antibodies, progranulin and prosaposin and a complex of both, and GDNF |
| EP4189095A1 (en) | 2020-07-27 | 2023-06-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| MX2023001137A (es) | 2020-07-29 | 2023-02-22 | Freeline Therapeutics Ltd | Beta-glucocerebrosidasa mutada con estabilidad mejorada. |
| US20230310654A1 (en) * | 2020-08-10 | 2023-10-05 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| IL300409A (en) | 2020-08-10 | 2023-04-01 | Prevail Therapeutics Inc | Gene therapies for neurodegenerative disorders |
| IL301858A (en) * | 2020-10-15 | 2023-06-01 | Prevail Therapeutics Inc | Assay for measuring potency of gene therapy drug product |
| KR20230088393A (ko) * | 2020-10-15 | 2023-06-19 | 프리베일 테라퓨틱스, 인크. | 재조합 아데노 연관 바이러스 조성물 및 이의 제조 방법 |
| WO2023091949A2 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| JP2025504478A (ja) * | 2022-01-21 | 2025-02-12 | アストラゼネカ アイルランド リミテッド | ゴーシェ病の遺伝子療法 |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| CN121127597A (zh) | 2023-05-03 | 2025-12-12 | 沃雅戈治疗公司 | 用于治疗与葡糖苷酰鞘氨醇酶β1缺陷相关的病症的组合物及方法 |
| WO2025038805A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| KR20250046126A (ko) * | 2023-09-22 | 2025-04-02 | 주식회사 스탠드업테라퓨티스 | 신규한 파킨슨 병 치료제 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US6521225B1 (en) | 1996-09-06 | 2003-02-18 | Chiron Corporation | AAV vectors |
| DE69941905D1 (de) | 1998-11-10 | 2010-02-25 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| US6696272B1 (en) | 1999-06-02 | 2004-02-24 | Hsc Research & Development Limited Partnership | Products and methods for gaucher disease therapy |
| GB0009887D0 (en) | 2000-04-20 | 2000-06-07 | Btg Int Ltd | Cytotoxic agents |
| WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| CA2423082A1 (en) * | 2000-09-18 | 2002-03-28 | Genzyme Corporation | Expression vectors containing hybrid ubiquitin promoters |
| US20030133924A1 (en) * | 2001-12-21 | 2003-07-17 | Novazyme Pharmaceuticals, Inc. | Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease |
| WO2003089612A2 (en) | 2002-04-17 | 2003-10-30 | University Of Florida Research Foundation, Inc. | IMPROVED rAAV VECTORS |
| PT1620133E (pt) | 2003-05-01 | 2016-03-31 | Genzyme Corp | Terapia genética para distúrbios neurometabólicos |
| WO2006036465A2 (en) | 2004-09-03 | 2006-04-06 | University Of Florida | Compositions and methods for treating cystic fibrosis |
| WO2006039253A2 (en) | 2004-09-29 | 2006-04-13 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
| MX364444B (es) | 2006-06-07 | 2019-04-26 | Genzyme Corp | Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la médula espinal. |
| EP2160403B1 (en) | 2007-05-11 | 2018-08-08 | Genzyme Corporation | Methods of producing a secreted protein |
| PL2154969T3 (pl) | 2007-05-16 | 2016-04-29 | Brigham & Womens Hospital Inc | Leczenie synukleinopatii |
| US20090176729A1 (en) | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| US9255266B2 (en) | 2009-05-06 | 2016-02-09 | Rutgers, The State University Of New Jersey | RNA targeting in alpha-synucleinopathies |
| WO2012027558A2 (en) | 2010-08-25 | 2012-03-01 | The Trustees Of Columbia University In The City Of New York | OPTIMIZED miRNA CONSTRUCTS |
| WO2012027713A2 (en) | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| EP2640407A4 (en) | 2010-11-16 | 2014-07-09 | Denis G Kay | PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN |
| CA2863829A1 (en) * | 2012-02-19 | 2013-08-22 | Protalix Ltd. | Oral unit dosage forms and uses of same for the treatment of gaucher disease |
| CN104902923A (zh) * | 2012-11-05 | 2015-09-09 | 建新公司 | 用于治疗蛋白质病的组合物和方法 |
| CA2912678C (en) | 2013-05-15 | 2023-10-10 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| US9347107B2 (en) | 2013-05-23 | 2016-05-24 | Norman Z Lai | Vector containing multiple nucleotide sequences for the expression of enzymes |
| US9574184B2 (en) * | 2013-09-25 | 2017-02-21 | Children's Hospital Medical Center | Lysosomal protein targeting sequence and therapeutic applications of same |
| WO2016081927A2 (en) * | 2014-11-21 | 2016-05-26 | University Of Florida Research Foundation, Inc. | Genome-modified recombinant adeno-associated virus vectors |
| US20170035860A1 (en) | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
| JP2015180203A (ja) * | 2015-04-17 | 2015-10-15 | ザ スクリプス リサーチ インスティテュート | タンパク質生産の増強のためのｍＲＮＡの一次構造の再操作 |
| US10967073B2 (en) | 2015-05-07 | 2021-04-06 | The Mclean Hospital Corporation | Glucocerebrosidase gene therapy for Parkinson's disease |
| EP3091087A1 (en) | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| SI3294323T1 (sl) | 2015-05-15 | 2022-06-30 | Regenxbio Inc. | Adenoasociacijski virus za terapevtsko dostavo v centralni živčni sistem |
| HK1258413A1 (zh) | 2015-10-29 | 2019-11-08 | Voyager Therapeutics, Inc. | 遞送中樞神經系統(cns)靶向多核苷酸 |
| WO2017077451A1 (en) * | 2015-11-05 | 2017-05-11 | Bamboo Therapeutics, Inc. | Modified friedreich ataxia genes and vectors for gene therapy |
| EP3411059A4 (en) | 2016-02-02 | 2019-10-16 | University Of Massachusetts | METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM |
| HRP20231451T1 (hr) | 2016-02-05 | 2024-03-01 | Emory University | Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu |
| JP7436089B2 (ja) | 2016-03-02 | 2024-02-21 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 前頭側頭型認知症の治療 |
| KR102709597B1 (ko) | 2017-10-03 | 2024-09-26 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
| AU2018346102B2 (en) | 2017-10-03 | 2023-05-11 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| IL273776B2 (en) | 2017-10-03 | 2025-06-01 | Prevail Therapeutics Inc | Gene therapies for lysosomal disorders |
| EP3701030A4 (en) | 2017-10-23 | 2022-04-20 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR NEURODEGENERATIVE DISEASES |
| BR112021020157A2 (pt) | 2019-04-10 | 2021-12-14 | Prevail Therapeutics Inc | Terapias gênicas para transtornos lisossomais |
| US20220211871A1 (en) | 2019-04-10 | 2022-07-07 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| AU2020270984B2 (en) | 2019-04-10 | 2025-11-20 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
-
2018
- 2018-10-03 IL IL273776A patent/IL273776B2/en unknown
- 2018-10-03 MX MX2020003557A patent/MX2020003557A/es unknown
- 2018-10-03 WO PCT/US2018/054225 patent/WO2019070893A1/en not_active Ceased
- 2018-10-03 CN CN201880075674.4A patent/CN111542549A/zh active Pending
- 2018-10-03 JP JP2020540682A patent/JP7254815B2/ja active Active
- 2018-10-03 IL IL278868A patent/IL278868B2/en unknown
- 2018-10-03 EP EP18865080.8A patent/EP3692075A4/en active Pending
- 2018-10-03 US US16/753,016 patent/US11802294B2/en active Active
- 2018-10-03 KR KR1020207012188A patent/KR102693318B1/ko active Active
- 2018-10-03 BR BR112020006633-8A patent/BR112020006633A2/pt unknown
- 2018-10-03 CA CA3078371A patent/CA3078371A1/en active Pending
- 2018-10-03 AU AU2018346104A patent/AU2018346104B2/en active Active
-
2019
- 2019-11-20 US US16/689,865 patent/US10837028B2/en active Active
-
2020
- 2020-07-13 MX MX2020011745A patent/MX2020011745A/es unknown
- 2020-07-14 AU AU2020205228A patent/AU2020205228B2/en active Active
- 2020-09-17 US US17/024,117 patent/US11060113B2/en active Active
-
2021
- 2021-07-07 US US17/369,168 patent/US20210332385A1/en active Pending
-
2023
- 2023-03-29 JP JP2023052515A patent/JP2023086740A/ja active Pending
-
2024
- 2024-12-13 JP JP2024218686A patent/JP2025063034A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537543A5 (OSRAM) | ||
| JP2020537542A5 (OSRAM) | ||
| JP2020537544A5 (OSRAM) | ||
| JP2022060228A5 (OSRAM) | ||
| JP7303287B2 (ja) | 新規アデノ随伴ウイルスキャプシドタンパク質 | |
| US11938197B2 (en) | Polynucleotides and vectors for the expression of transgenes | |
| FI3684423T3 (fi) | Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä | |
| US20160243260A1 (en) | Treatment of neurological diseases using adeno-associated virus (AAV) comprising AAV-5 capsid proteins | |
| IL273776B2 (en) | Gene therapies for lysosomal disorders | |
| RU2021102893A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
| TW202005978A (zh) | 新穎肝靶向腺相關病毒載體 | |
| US20060003453A1 (en) | High-efficiency AAV helper functions | |
| US20230049066A1 (en) | Novel aav3b variants that target human hepatocytes in the liver of humanized mice | |
| US20240318199A1 (en) | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders | |
| TW202246516A (zh) | 病毒蛋白之控制表現 | |
| TW202229315A (zh) | 改良的腺相關病毒(aav)載體及其用途 | |
| CN119487183A (zh) | 用于生产重组细小病毒的组合物和方法 | |
| CA3122319A1 (en) | Expression cassettes for gene therapy vectors | |
| AU2023406927A1 (en) | Adeno-associated viral vectors for proper packaging of repetitive elements | |
| EP4582546A1 (en) | Adeno-associated virus structural plasmid capable of improving adeno-associated virus titer | |
| JP2022529701A (ja) | 新型の酵素組成物 | |
| CN111527201A (zh) | 修饰的病毒载体及其制备和使用方法 | |
| CN118414348A (zh) | 经修饰的aav衣壳和载体 | |
| JP2023539247A (ja) | Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 | |
| US20240425879A1 (en) | Compositions and methods for adeno-associated (aav) virus dnase expression |